Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering

Rhea-AI Summary

Silexion Therapeutics (NASDAQ: SLXN), a clinical-stage biotech focused on RNA interference therapies for KRAS-driven cancers, has announced the pricing of a $6.0 million public offering. The offering includes 1,500,000 ordinary shares (or equivalents) with accompanying series A and B warrants at $4.00 per share.

The offering includes series A warrants with a 5-year term and series B warrants with a 12-month term, both with a $4.00 exercise price. H.C. Wainwright & Co. is serving as the exclusive placement agent. The proceeds will support pre-clinical studies and general corporate purposes, with closing expected around September 12, 2025.

Positive

• Secured $6.0 million in gross proceeds to advance pre-clinical studies
• Successful registration of Form S-1 with SEC approval
• Strategic funding to advance RNAi therapies for KRAS-driven cancers

Negative

• Potential dilution for existing shareholders through new share issuance
• Additional dilution risk from 3 million total warrants if exercised
• Relatively small offering size may indicate limited investor interest

Insights

Biotech Investment Analyst

Silexion's $6M offering provides short-term funding for pre-clinical RNAi cancer therapies but dilutes existing shareholders significantly.

Silexion Therapeutics has priced a $6 million public offering through a combination of ordinary shares and warrants, a relatively modest capital raise for a clinical-stage biotech. The company is selling 1,500,000 shares (or equivalents) at $4.00 per share, bundled with two series of warrants that could potentially lead to an additional 3 million shares being issued if exercised.

This financing structure merits careful consideration. The inclusion of both short-term (12-month) and long-term (5-year) warrants at the same $4.00 exercise price suggests the company needed to offer significant incentives to attract investors. This typically indicates challenging market conditions or investor hesitation about the company's prospects.

For context, this $6 million gross raise (before deducting placement agent fees and expenses) is likely to translate to approximately $5.4-5.5 million in net proceeds. For a company developing RNAi therapies targeting KRAS mutations - one of the most significant and challenging oncology targets - this amount provides limited runway. Pre-clinical development for RNA therapeutics typically requires substantial capital before reaching value-inflection clinical milestones.

The dilutive impact is notable, with the potential for significant additional dilution if warrants are exercised. This financing indicates Silexion is prioritizing near-term capital needs over concerns about dilution, suggesting urgency in securing funds for operations and pre-clinical advancement.

Grand Cayman, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the pricing of a public offering of an aggregate of  1,500,000 of the Company’s ordinary shares (or ordinary share equivalents), series A warrants to purchase up to  1,500,000 ordinary shares and series B warrants to purchase up to 1,500,000 ordinary shares at a combined public offering price of $4.00 per share (or per ordinary share equivalent) and accompanying warrants. The series A warrants will have an exercise price of $4.00 per share, will be exercisable immediately upon issuance and will expire five years from the date of issuance. The series B warrants will have an exercise price of $4.00 per share, will be exercisable immediately upon issuance and will expire twelve months from the date of issuance. The closing of the offering is expected to occur on or about September 12, 2025, subject to the satisfaction of customary closing conditions.

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

The gross proceeds from the offering, before deducting the placement agent's fees and other offering expenses, are expected to be $6.0 million.  The Company intends to use the net proceeds from this offering to advance the Company’s pre-clinical studies, and for general corporate purposes.

The securities described above are being offered pursuant to a registration statement on Form S-1 (File No. 333-290074), which was declared effective by the Securities and Exchange Commission (the “SEC”) on September 11, 2025. The offering is being made only by means of a prospectus forming part of the effective registration statement relating to the offering. A preliminary prospectus relating to the offering has been filed with the SEC. Electronic copies of the final prospectus, when available, may be obtained on the SEC’s website at http://www.sec.gov and may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Silexion Therapeutics

Silexion Therapeutics is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its first-generation product which showed a positive trend in comparison to the control of chemotherapy alone. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology, and further developing its lead product candidate for locally advanced pancreatic cancer. For more information please visit: https://silexion.com

Notice Regarding Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this communication, including statements regarding Silexion's business strategy, the completion of the offering, the satisfaction of customary closing conditions related to the offering, and the intended use of net proceeds from the offering, are forward-looking statements. These forward-looking statements are generally identified by terminology such as "may", "should", "could", "might", "plan", "possible", "project", "strive", "budget", "forecast", "expect", "intend", "will", "estimate", "anticipate", "believe", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) Silexion's ability to successfully complete preclinical studies and initiate clinical trials; (ii) Silexion's strategy, future operations, financial position, projected costs, prospects, and plans; (iii) the impact of the regulatory environment and compliance complexities; (iv) expectations regarding future partnerships or other relationships with third parties; (v) Silexion's future capital requirements and sources and uses of cash, including its ability to obtain additional capital; (vi) Silexion's ability to maintain its Nasdaq listing; and (vii) other risks and uncertainties set forth in the documents filed or to be filed with the SEC by the Company, including the Company's Quarterly Report on Form 10-K for the year ended December 31, 2024. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in circumstances, or changes in beliefs, except as otherwise required by law.

Company Contact:

Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com

Capital Markets & IR Contact:

ARX | Capital Markets Advisors
North American Equities Desk
silexion@arxadvisory.com

FAQ

What is the size and price of Silexion Therapeutics (SLXN) public offering in September 2025?

Silexion Therapeutics priced a $6.0 million public offering at $4.00 per share, consisting of 1,500,000 ordinary shares with accompanying series A and B warrants.

How will SLXN use the proceeds from its September 2025 offering?

Silexion Therapeutics will use the net proceeds to advance pre-clinical studies and for general corporate purposes.

What are the terms of SLXN's warrants in the September 2025 offering?

The offering includes series A warrants with a 5-year term and series B warrants with a 12-month term, both with an exercise price of $4.00 per share.

Who is the placement agent for Silexion Therapeutics' September 2025 offering?

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

What type of therapies is Silexion Therapeutics (SLXN) developing?

Silexion Therapeutics is developing RNA interference (RNAi) therapies specifically targeting KRAS-driven cancers.